Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials

Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Mcilraith M, Hu C, Edwards C, Birbara C, Mease P (2016)

Publication Type: Conference contribution

Publication year: 2016

Journal

Journal of Rheumatology Journal of Rheumatology

Book Volume: 43

Pages Range: 1169-1169

Journal Issue: 6

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

University of Sheffield

United Kingdom (GB) University Hospital Southampton NHS

United Kingdom (GB) Celgene Corporation

United States (USA) (US) University of Massachusetts Amherst (UMass)

United States (USA) (US) Complejo Hospitalario Universitario de Santiago de Compostela

Spain (ES) University of Toronto

Canada (CA) Schön Klinik Hamburg Eilbek

Germany (DE) University of Orléans / Université d'Orléans

France (FR) University of Genova / Università degli Studi di Genova

Italy (IT) University of California, San Diego

United States (USA) (US) Swedish Medical Center

United States (USA) (US)

How to cite

APA:

Gladman, D., Kavanaugh, A., Adebajo, A., Gomez-Reino, J., Wollenhaupt, J., Cutolo, M.,... Mease, P. (2016). Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials. (pp. 1169-1169).

MLA:

Gladman, Dafna, et al. "Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials." 2016. 1169-1169.

BibTeX: Download